Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to announce earnings of ($0.48) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Allena Pharmaceuticals’ earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.57). Allena Pharmaceuticals reported earnings of ($0.46) per share in the same quarter last year, which would suggest a negative year over year growth rate of 4.3%. The firm is expected to announce its next quarterly earnings report on Wednesday, November 6th.
Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Allena Pharmaceuticals.
Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.01).
Several brokerages have weighed in on ALNA. Credit Suisse Group dropped their price objective on Allena Pharmaceuticals from $26.00 to $7.00 and set an “outperform” rating for the company in a report on Friday, September 6th. Wedbush reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Allena Pharmaceuticals in a report on Thursday, October 17th. Zacks Investment Research cut Allena Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Monday, October 14th. Roth Capital dropped their price objective on Allena Pharmaceuticals from $61.00 to $31.00 in a report on Thursday, August 8th. Finally, ValuEngine raised Allena Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.96.
Several institutional investors have recently bought and sold shares of ALNA. Wedbush Securities Inc. acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth $63,000. Jane Street Group LLC acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth $116,000. Susquehanna International Group LLP acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth $137,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Allena Pharmaceuticals by 17.0% during the 2nd quarter. Jacobs Levy Equity Management Inc. now owns 41,587 shares of the company’s stock worth $169,000 after buying an additional 6,030 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new position in shares of Allena Pharmaceuticals during the 2nd quarter worth $212,000. 65.36% of the stock is owned by institutional investors.
Shares of NASDAQ ALNA opened at $5.42 on Wednesday. The stock has a market capitalization of $125.79 million, a PE ratio of -3.15 and a beta of 1.91. The company has a debt-to-equity ratio of 0.22, a current ratio of 6.80 and a quick ratio of 6.80. The business has a fifty day moving average price of $4.27 and a two-hundred day moving average price of $4.77. Allena Pharmaceuticals has a fifty-two week low of $3.33 and a fifty-two week high of $10.66.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults.
Featured Article: Does a trade war provide a risk to the global economy?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.